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Abstract
Background: In the elderly, chronic low-grade inflammation (inflammaging) is a risk factor for the development of
aging-related diseases and frailty. Using data from several thousand Eastern Europeans aged 65 years and older, we
investigated whether the serum levels of two proinflammatory factors, interleukin-6 (IL-6) and C-reactive protein (CRP),
were associated with physical and cognitive performance, and could predict mortality in successfully aging elderly.
Results: IL-6 and CRP levels systematically increased in an age-dependent manner in the entire study group (IL-6:
n = 3496 individuals, p < 0.001 and CRP: n = 3632, p = 0.003), and in the subgroup of successfully aging individuals
who had never been diagnosed with cardiovascular disease, myocardial infarction, stroke, type 2 diabetes, or cancer, and
had a Mini Mental State Examination (MMSE) score ≥24 and a Katz Activities of Daily Living (ADL) score ≥5 (IL-6: n= 1258,
p < 0.001 and CRP: n = 1312, p < 0.001). In the subgroup of individuals suffering from aging-related diseases/disability, only
IL-6 increased with age (IL-6: n = 2238, p < 0.001 and CRP: n = 2320, p = 0.249). IL-6 and CRP levels were lower in
successfully aging individuals than in the remaining study participants (both p < 0.001). Higher IL-6 and CRP levels
were associated with poorer physical performance (lower ADL score) and poorer cognitive performance (lower
MMSE score) (both p < 0.001). This association remained significant after adjusting for age, gender, BMI, lipids,
estimated glomerular filtration rate, and smoking status. Longer survival was associated with lower concentrations
of IL-6 and CRP not only in individuals with aging-related diseases/disability (HR = 1.063 per each pg/mL, 95 % CI:
1.052-1.074, p < 0.001 and HR = 1.020 per each mg/L, 95 % CI: 1.015-1.025, p < 0.001, respectively) but also in the
successfully aging subgroup (HR = 1.163 per each pg/mL, 95 % CI: 1.128-1.199, p < 0.001 and HR = 1.074 per each
mg/L, 95 % CI: 1.047-1.100, p < 0.001, respectively). These associations remained significant after adjusting for age,
gender, BMI, lipids and smoking status. The Kaplan-Meier survival curves showed similar results (all p < 0.001).
Conclusions: Both IL-6 and CRP levels were good predictors of physical and cognitive performance and the risk of
mortality in both the entire elderly population and in successfully aging individuals.
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Background
Immunosenescence is an integral part of human aging
that results in a decrease in the number of naive T and B
lymphocytes, the accumulation of memory and effector
T and B cells, the production of defective antibodies, an
increase in the production of autoantibodies, and in
chronic low-grade inflammation (inflammaging) [1, 2].
Among the probable triggers of inflammaging are chronic
viral infections, an aging-related increase in adiposity,
dietary habits and aging-related changes in the compos-
ition of the gut microbiota [3–5]. Among its most import-
ant features are slight elevations of the concentrations of
proinflammatory cytokines, chemokines, and adipokines,
such as interleukin-1ß (IL-1ß), interleukin-6 (IL-6), tumor
necrosis factor-α (TNF-α), and monocyte chemoattractant
protein-1 (chemokine (C-C motif) ligand 2, CCL2) [6–8].
Proinflammatory cytokines stimulate the synthesis of C-
reactive protein (CRP) in the liver, the level of which has
been shown to increase in elderly individuals [9]. While
clinical signs and symptoms of inflammaging are minimal
or absent, this condition contributes to various molecular
pathologies, leading to vascular damage and insulin re-
sistance [10–12] and, therefore, increases the risk of de-
veloping type 2 diabetes, cardiovascular disease, stroke,
cancer, sarcopenia, neurodegeneration, and frailty [13–22].
Furthermore, low-grade inflammation predicts mortality
in elderly individuals who are affected by various patholo-
gies [15, 17, 23–25].
IL-6 and CRP are among the most commonly used indi-
cators of inflammation. However, while some published
data suggest their causal or predictive roles in morbidity
or mortality in the elderly, other studies do not support
such views [26–29]. Moreover, the literature on the effects
of inflammaging on mortality in successfully aging individ-
uals is not extensive. Therefore, the main objective of the
present work was to investigate whether the results of a
single measurement of IL-6 and CRP levels were associ-
ated with mortality in elderly participants of the PolSenior
study who were followed for an average of 4.3 years, with
a particular emphasis on individuals who had never been
diagnosed with aging-related diseases and remained in
good physical and cognitive health. Another aim of this
study was to determine possible associations between the
concentrations of these factors and cognitive and physical
functioning, which were assessed at the same time. Finally,
we evaluated whether low-dose acetylsalicylic acid, which
is frequently prescribed to seniors for the prevention of car-
diovascular disease, affects IL-6 and CRP concentrations.
Methods
Material
The study group consisted of ≥65 year old seniors (n =
4979 individuals) who participated in the PolSenior
study. The participants were randomly recruited in
bundles in a stratified, proportional draw. The response
rate was 42.6 %. The recruitment details are described
elsewhere [30]. The respondents belonged to similarly-
sized age groups (65–69, 70–74, 75–79, 80–84, 85–89
and ≥90 years old), each containing a similar number of
males and females. A detailed questionnaire was used to
obtain medical histories, current health status, socioeco-
nomic status, demographic status, and lifestyle habits for
all of the study participants. The participants also under-
went a detailed examination, including elements of com-
prehensive geriatric assessment [30]. Individuals who had
never been diagnosed with cardiovascular disease, myo-
cardial infarction, stroke, type 2 diabetes, or cancer, and
had a Mini Mental State Examination (MMSE) score ≥24
and Katz Activities of Daily Living (ADL) score ≥5 were
classified as successfully aging. Of the entire group, blood
samples were provided by 4101 individuals. Blood collec-
tion, surveys, and physical examinations were performed
either on the same day or within a few days of each other.
The survival of the study subjects was taken from the
Population Register. This database was accessed in 2015,
indicating that 1734 PolSenior participants (1318 of
those who donated blood) had died. The total number
of person-years of observation was 14,535.
The PolSenior project was approved by the Bioethics
Commission of the Medical University of Silesia in
Katowice. Each participant gave written, informed con-
sent to participate in the study.
Blood analysis
Venous blood was collected using a vacuum system and
delivered in a cooler to local laboratories within 2 h,
where serum and plasma samples were separated and
frozen. All samples were then delivered to the Department
of Human Epigenetics, Mossakowski Medical Research
Centre in Warsaw. All of the IL-6 and CRP measurements
were performed in the same laboratory. Interleukin-6 levels
were measured in serum using ELISA (R&D System,
Minneapolis, MN, USA, sensitivity 0.04 pg/mL) in 3895
individuals and CRP (high sensitivity CRP) levels were
measured using a high-sensitivity immunoturbidymetric
method (Modular PPE, Roche Diagnostics GmBH,
Mannheim, Germany, sensitivity 0.11 mg/L) in 4093 in-
dividuals. In the other PolSenior participants, these mea-
surements were not performed mostly because of refusal
to provide blood or because an insufficient amount of
serum was collected. Other biochemical parameters were
assessed using routine techniques [30]. Study subjects
with leukocyte counts >10,000/μL (indicating a consider-
able risk of ongoing infection) and/or who were being
treated with glucocorticoids were excluded from further
analyses. Therefore, analyses of IL-6 were performed in
3496 subjects, and of CRP were performed in 3632 sub-
jects. In some of the study subjects, only IL-6 or only CRP
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was measured. The results were presented as median
[1st quartile, 3rd quartile] values.
Mini mental state examination and activities of
daily living
Cognitive function was assessed using the MMSE [31]
which was translated into Polish. The study participants
were divided into five groups: normal cognition (MMSE
score 28–30), minimal cognitive impairment (MMSE score
24–27), mild (MMSE score 20–23), moderate (MMSE
score 10–19), or severe (MMSE score <10) cognitive
impairment [32].
Physical performance was assessed using the ADL scale
[33]. Based on the six domains of the ADL (transferring,
feeding, bathing, dressing, personal hygiene and groom-
ing, toileting), the study participants were divided into in-
dependent (ADL score 5–6), partially dependent (ADL
score 3–4) and totally dependent (ADL score 0–2) [34].
Statistical analysis
The statistical analyses were performed using Statistica
10 software (Statsoft Inc., Tulsa, OK, USA) and R soft-
ware (R Foundation for Statistical Computing, Vienna,
Austria) programs. Because of the skewed distribution of
the IL-6 and CRP values, the variables were presented as
median [1st quartile, 3rd quartile] values. Before the ana-
lyses, the IL-6 and CRP values were log-transformed.
The significance of associations between the analyzed
factors was tested using analysis of variance (ANOVA),
and analysis of co-variance (ANCOVA) for multifactorial
analyses. Pearson’s r was used as a measure of correla-
tions between IL-6 and CRP levels.
A Kaplan-Meier plots were used to present survival
curves, which were compared using the log-rank test.
The Cox proportional hazards model was used for uni-
variate survival analyses. In the multivariate survival ana-
lyses, age and body mass index (BMI) did not meet the
assumption of proportional hazards. Therefore, the Cox
proportional hazards model with time-dependent covari-
ates was used. The hazard ratio (HR) of death and the
95 % confidence interval (CI) were calculated for associ-
ations between the analyzed variables and survival time.
For all of the statistical analyses, the level of signifi-
cance was established at 0.05.
Results
Aging-associated changes in serum IL-6 and CRP levels
The mean age of all the study participants who met the in-
clusion criteria (3750 individuals, 47.8 % women, 52.2 %
men) was 78.9 ± 8.6 years. The mean age of the successfully
aging subgroup (35.4 % of the study population; 47.4 %
women, 52.6 % men) was 76.3 ± 7.9 years, while in the
remaining study participants who did not meet our defin-
ition of successful aging (64.6 % of the study population;
48 % women, 52 % men) was 80.3 ± 8.6 years. The age dif-
ference between the successfully aging participants and the
remaining study participants was significant (p < 0.001).
Low-dose acetylsalicylic acid is commonly prescribed
to seniors for the prevention of cardiovascular disease.
We initially determined whether this medication affects
IL-6 or CRP concentrations and whether individuals
who received it should be included in the analysis or an-
alyzed separately. The comparison between individuals
who were not currently treated with low-dose acetylsali-
cylic acid vs. individuals who took this medication showed
that the median concentrations of IL-6 were similar in
both groups (2321 individuals, 2.3 pg/mL [1.5, 3.8] vs.
1175 individuals, 2.4 pg/mL [1.6, 3.8], respectively, p =
0.22), as were the median CRP values (2410 individ-
uals, 2.3 mg/L [1.1, 4.8] vs. 1222 individuals, 2.3 mg/L
[1.1, 4.7], respectively, p = 0.73). Therefore, all of the
subsequent analyses were performed without considering
whether the participants were treated with low-dose
acetylsalicylic acid.
The median concentration of IL-6 in the entire study
group (3496 individuals) was 2.3 pg/mL [1.5, 3.8]. In
successfully aging study participants (1258 individuals) it
was 2.0 pg/mL [1.3, 3.3], while in participants who suf-
fered from aging-related diseases/disability (2238 indi-
viduals) it was 2.5 pg/mL [1.6, 4.2]. This difference was
significant (p < 0.001). We also found that the older the
age group, the higher was the median concentration of
IL-6 not only in the entire study group and in individ-
uals with aging-related diseases/disability, but also in the
subgroup of successfully aging individuals (all p < 0.001,
Table 1).
The median CRP concentration in the entire study group
(3632 individuals) was 2.3 mg/L [1.1, 4.7]. The subgroups
of successfully aging participants (1312 individuals) and
those who did not meet the definition of successful aging
(2320 individuals) had median concentrations 2.1 mg/L
[1.0, 4.3] and 2.5 mg/L [1.1, 5.1], respectively. This dif-
ference that was significant (p < 0.001). In the entire
study group, we observed a significant increase in the
median CRP concentration as age increased (p = 0.003).
Notably, the median CRP concentration was higher in
≥80 year old study participants than in younger age groups.
In the study participants with aging-related diseases/dis-
ability, the median CRP level was not associated with age
(p = 0.25). In the successfully aging subgroup, the median
CRP levels were also higher in the older age groups, but
the level of significance has not been reached (p = 0.09)
(Table 1).
IL-6 and CRP levels were correlated with each other
in the entire study group (r = 0.502, p < 0.001), the
successfully aging subgroup (r = 0.538, p < 0.001), and
study participants with aging-related diseases/disability
(r = 0.504, p < 0.001).
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We also evaluated whether IL-6 and CRP concentrations
differed in women and men and found that the median
IL-6 concentrations were higher in men (1673 women,
2.2 pg/mL [1.5, 3.6] vs. 1823 men, 2.4 pg/mL [1.6, 4.0],
p = 0.006), whereas the median CRP concentrations
were not significantly different (1735 women, 2.4 mg/L
[1.2, 4.7] vs. 1897 men, 2.2 mg/L [1.0, 4.9], p = 0.25).
Association between the IL-6 and CRP levels and other
biochemical parameters and functional and cognitive
performance
IL-6 concentrations were significantly associated with
BMI (p < 0.001 for the entire study group, p = 0.015 for
the successfully aging subgroup, and p = 0.007 for study
participants with aging-related diseases/disability). Not-
ably, in individuals with a BMI <18.5 kg/m2, the median
IL-6 value was the highest, while in overweight individ-
uals it was the lowest, and again increased in the obese.
In addition, the median IL-6 value was associated with
estimated glomerular filtration rate (eGFR) (p < 0.001 for
the entire study group, p < 0.001 for the successfully
aging subgroup, and p < 0.001 for study participants with
aging-related diseases/disability) and was the highest in
individuals with the lowest eGFR, as well as with heart
rate (p < 0.001, p < 0.001 and p < 0.001) where it was the
highest in individuals with a heart rate >80/min. It was
also associated with smoking status (p = 0.02 for the entire
study group and p = 0.016 for participants with aging-
related diseases/disability); it was the highest in current
smokers. No association with smoking status was found in
the successfully aging subgroup. Of note, the IL-6 concen-
tration was negatively associated with total cholesterol
levels (p < 0.001 for the entire study group, p < 0.001 for
the successfully aging subgroup, and p < 0.001 for study
participants with aging-related diseases/disability), LDL
cholesterol (p < 0.001, p = 0.007 and p < 0.001), and HDL
cholesterol (p < 0.001, p < 0.001 and p < 0.001) (Table 2).
The multifactorial analysis including age, gender, BMI,
HDL, LDL, eGFR and smoking status, showed that only
gender lost its significant association with IL-6 in the en-
tire study group. In the successfully aging subgroup, gen-
der and LDL lost their associations with IL-6, while in
participants with aging-related diseases/disability the asso-
ciation was lost for gender and eGFR. The other factors
remained significantly associated with IL-6.
We also evaluated whether IL-6 concentrations were
related to functional and cognitive performance. We found
that higher IL-6 levels were associated with poorer physical
performance (lower ADL score) and poorer cognitive per-
formance (lower MMSE score) (all p < 0.001 for the entire
study group as well as for both subgroups) (Table 2). He
multifactorial analyses that were adjusted for age, gender,
BMI, HDL, LDL, eGFR and smoking status revealed
that ADL and MMSE scores in the entire studied group
remained associated with IL-6 (p = 0.006 and p = 0.007,
respectively). Such an analysis was not performed sep-
arately in the successfully aging subgroup because only
individuals with the highest ADL and MMSE scores,
Table 1 IL-6 and CRP concentrations in ≥65 year-old seniors
Age (years) Alla Successfully agingb Othersc
n Concentrationd n Concentrationd n Concentrationd
IL-6 [pg/mL]
65–69 588 1.8 [1.2, 2.9] 296 1.8 [1.1, 3.0] 292 1.9 [1.3, 2.9]
70–74 681 1.9 [1.3, 3.1] 308 1.7 [1.1, 2.8] 373 2.2 [1.4, 3.3]
75–79 596 2.1 [1.4, 3.4] 231 1.9 [1.3, 2.8] 365 2.4 [1.6, 3.6]
80–84 557 2.5 [1.7, 3.7] 163 2.4 [1.5, 3.5] 394 2.5 [1.7, 3.8]
85–89 598 2.8 [1.8, 4.9] 173 2.7 [1.8, 4.3] 425 2.8 [1.8, 5.1]
90+ 476 3.5 [2.1, 5.5] 87 3.3 [2.3, 5.1] 389 3.5 [2.1, 5.6]
CRP [mg/L]
65–69 614 2.2 [1.1, 4.6] 311 2.0 [1.0, 4.1] 303 2.6 [1.2, 5.5]
70–74 706 2.1 [1.1, 4.1] 321 1.9 [1.0, 3.9] 385 2.2 [1.1, 4.4]
75–79 627 2.2 [1.1, 4.4] 245 1.9 [1.0, 3.8] 382 2.6 [1.2, 4.8]
80–84 572 2.4 [1.1, 5.2] 169 2.4 [1.0, 5.3] 403 2.3 [1.1, 5.2]
85–89 621 2.5 [1.1, 5.1] 177 2.8 [1.2, 4.6] 444 2.4 [1.1, 5.2]
90+ 492 2.7 [1.1, 5.5] 89 2.6 [1.3, 5.3] 403 2.7 [1.1, 5.7]
a: Excluded are individuals with leukocytosis exceeding 10,000/μL or treated with glucocorticoids
b: Only individuals without past or current cancer, type 2 diabetes, cardiovascular disease/myocardial infarction/stroke, and with the MMSE score ≥24 and the ADL
score 5–6
c: Individuals who did not meet the definition of successful aging
d: Concentrations of IL–6 and CRP are shown as median [1st quartile, 3rd quartile]
n number of individuals
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Table 2 IL-6 and CRP concentration in ≥65 year-old seniors in relation to select clinical and biochemical parameters, and functional status
IL-6 [pg/mL] CRP [mg/L]
Alla Successfully agingb Othersc Alla Successfully agingb Othersc
n Concentrationd n Concentrationd n Concentrationd n Concentrationd n Concentrationd n Concentrationd
BMI [kg/m2] <18.5 60 3.2 [1.8, 5.4] 21 3.2 [1.7, 4.8] 39 3.2 [1.9, 5.7] 64 2.3 [1.0, 7.4] 21 1.8 [0.7, 7.5] 43 2.5 [1.0, 7.2]
18.5-24.9 814 2.3 [1.4, 3.9] 315 1.9 [1.2, 3.2] 499 2.5 [1.6, 4.5] 865 1.7 [0.8, 3.8] 336 1.5 [0.8, 3.0] 529 1.8 [0.9, 4.3]
25–29.9 1381 2.2 [1.4, 3.5] 548 1.9 [1.3, 3.2] 833 2.3 [1.5, 3.8] 1425 2.1 [1.0, 4.2] 569 2.0 [1.0, 4.0] 856 2.2 [1.0, 4.3]
30–39.9 997 2.3 [1.6, 3.6] 343 2.2 [1.4, 3.6] 654 2.4 [1.7, 3.6] 1025 2.8 [1.5, 5.2] 354 2.9 [1.6, 5.4] 671 2.7 [1.4, 5.1]
≥40 69 2.8 [2.1, 4.1] 17 2.5 [1.9, 3.4] 52 2.9 [2.1, 4.9] 69 4.2 [2.2, 8.8] 17 4.3 [2.5, 7.8] 52 4.1 [2.1, 9.1]
Cholesterol [mg/dL] <175 1029 2.7 [1.7, 4.8] 256 2.4 [1.5, 4.4] 773 2.8 [1.8, 5.1] 1085 2.3 [1.0, 5.3] 267 2.2 [1.0, 5.0] 818 2.4 [1.0, 5.3]
175–189 452 2.3 [1.6, 3.8] 178 2.2 [1.4, 3.7] 274 2.4 [1.7, 3.8] 478 2.4 [1.1, 5.1] 184 1.9 [1.0, 4.2] 294 2.6 [1.1, 5.7]
190–239 1302 2.2 [1.5, 3.5] 512 2.0 [1.3, 3.1] 790 2.4 [1.6, 3.8] 1375 2.2 [1.1, 4.4] 543 2.2 [1.0, 4.1] 832 2.3 [1.1, 4.7]
240–309 593 2.0 [1.4, 3.1] 275 1.8 [1.2, 2.7] 318 2.2 [1.5, 3.4] 627 2.3 [1.2, 4.5] 291 2.1 [1.2, 4.0] 336 2.7 [1.4, 5.2]
≥310 65 2.2 [1.4, 3.6] 27 2.4 [1.4, 3.7] 38 2.2 [1.5, 3.6] 67 3.3 [1.5, 5.2] 27 2.1 [1.0, 5.0] 40 3.6 [1.7, 5.3]
HDL [mg/dL] <40 774 3.0 [1.8, 4.9] 199 2.7 [1.6, 3.9] 575 3.1 [1.9, 5.3] 822 2.9 [1.4, 6.2] 211 2.6 [1.3, 5.4] 611 3.0 [1.5, 6.5]
40–44 525 2.6 [1.7, 4.4] 168 2.4 [1.6, 4.0] 357 2.7 [1.8, 4.5] 549 2.4 [1.2, 5.0] 176 2.3 [1.3, 4.7] 373 2.4 [1.2, 5.1]
45–49 528 2.4 [1.6, 4.0] 190 2.1 [1.3, 3.5] 338 2.6 [1.8, 4.2] 549 2.5 [1.1, 5.3] 201 2.5 [1.1, 4.8] 348 2.4 [1.2, 5.9]
50–59 851 2.1 [1.4, 3.4] 362 1.9 [1.3, 3.2] 489 2.2 [1.5, 3.4] 900 2.2 [1.1, 4.2] 370 2.1 [1.0, 3.9] 530 2.3 [1.1, 4.3]
≥60 760 1.8 [1.2, 3.0] 328 1.7 [1.1, 2.6] 432 2.0 [1.3, 3.3] 810 1.8 [0.8, 3.6] 353 1.6 [0.8, 3.1] 457 1.9 [0.9, 4.1]
LDL [mg/dL] <70 329 2.8 [1.8, 5.1] 53 2.2 [1.6, 3.6] 276 2.9 [1.9, 5.5] 347 2.4 [0.9, 4.9] 55 2.4 [0.7, 5.0] 292 2.4 [1.0, 4.9]
71–99 809 2.5 [1.6, 4.2] 234 2.2 [1.5, 4.1] 575 2.6 [1.6, 4.2] 860 2.3 [1.0, 4.7] 249 1.9 [1.0, 4.3] 611 2.4 [1.0, 5.0]
100–114 506 2.3 [1.6, 4.0] 204 2.1 [1.3, 3.6] 302 2.5 [1.7, 4.3] 530 2.1 [1.0, 4.8] 214 2.1 [1.0, 4.2] 316 2.1 [1.0, 5.1]
115–154 1168 2.2 [1.4, 3.5] 463 1.9 [1.3, 3.1] 705 2.4 [1.6, 3.7] 1234 2.2 [1.1, 4.6] 485 2.1 [1.0, 4.0] 749 2.5 [1.2, 5.1]
155–189 468 2.1 [1.5, 3.3] 218 1.9 [1.3, 2.9] 250 2.2 [1.6, 3.8] 494 2.5 [1.4, 4.6] 230 2.3 [1.2, 4.1] 264 2.7 [1.5, 5.5]
≥190 159 2.1 [1.3, 3.2] 75 1.8 [1.2, 3.0] 84 2.2 [1.5, 3.4] 166 2.7 [1.2, 5.4] 78 2.3 [1.2, 5.4] 88 3.0 [1.3, 5.4]
Glucose [mg/dL] <100 2133 2.3 [1.5, 3.8] 924 2.0 [1.3, 3.3] 1209 2.5 [1.7, 4.4] 2261 2.2 [1.0, 4.6] 966 2.1 [1.0, 4.1] 1295 2.4 [1.1, 5.0]
100–139.9 1042 2.4 [1.6, 3.7] 324 2.1 [1.4, 3.4] 718 2.5 [1.6, 3.8] 1089 2.3 [1.1, 4.8] 346 2.2 [1.1, 4.8] 743 2.4 [1.1, 4.9]
≥140 256 2.5 [1.7, 4.1] na na 256 2.5 [1.7, 4.1] 272 3.0 [1.4, 6.8] na na 272 3.0 [1.4, 6.8]
eGFR [mL/min/ 1.73 m2] <45 359 3.2 [2.1, 5.3] 70 3.8 [2.6, 6.7] 289 3.0 [2.0, 5.2] 378 3.2 [1.5, 6.3] 77 3.5 [1.9, 6.3] 301 3.0 [1.5, 6.3]
45–60 639 2.7 [1.7, 4.1] 187 2.4 [1.5, 3.6] 452 2.8 [1.8, 4.5] 668 2.5 [1.1, 5.4] 192 2.2 [1.1, 4.4] 476 2.7 [1.2, 6.2]
>60 2421 2.1 [1.4, 3.5] 977 1.9 [1.3, 3.1] 1444 2.3 [1.6, 3.8] 2531 2.2 [1.0, 4.4] 1019 2.0 [1.0, 4.1] 1512 2.3 [1.0, 4.7]
Heart rate [per min] <60 341 2.2 [1.5, 3.6] 126 1.8 [1.2, 2.9] 215 2.6 [1.6, 4.0] 354 1.6 [0.9, 3.6] 131 1.8 [1.0, 3.6] 223 1.5 [0.9, 3.6]
60–80 2374 2.2 [1.5, 3.6] 893 2.0 [1.3, 3.2] 1481 2.3 [1.6, 3.8] 2463 2.3 [1.0, 4.5] 929 2.1 [1.0, 4.0] 1534 2.4 [1.1, 4.9]
>80 768 2.7 [1.7, 4.8] 239 2.4 [1.5, 4.0] 529 2.8 [1.8, 5.1] 801 3.0 [1.4, 6.2] 252 2.7 [1.3, 5.6] 549 3.1 [1.4, 6.3]
Smoking Never 1968 2.3 [1.5, 3.7] 689 1.9 [1.3, 3.1] 1279 2.4 [1.6, 4.1] 2035 2.3 [1.1, 4.5] 710 2.1 [1.0, 3.9] 1325 2.4 [1.1, 4.9]
Puzianow
ska-Kuźnicka
et
al.Im
m
unity
&
A
geing
 (2016) 13:21 
Page
5
of
12
Table 2 IL-6 and CRP concentration in ≥65 year-old seniors in relation to select clinical and biochemical parameters, and functional status (Continued)
Past 1196 2.4 [1.5, 3.8] 424 2.0 [1.4, 3.3] 772 2.5 [1.6, 4.0] 1250 2.2 [1.0, 4.8] 450 2.1 [1.0, 4.5] 800 2.3 [1.0, 5.0]
Current 304 2.7 [1.7, 4.5] 140 2.4 [1.4, 3.7] 164 3.0 [1.8, 5.2] 319 3.1 [1.3, 6.2] 147 2.4 [1.1, 5.1] 172 3.4 [1.5, 7.7]
MMSE [points] 28–30 1121 1.9 [1.3, 3.1] 606 1.9 [1.2, 3.0] 515 2.0 [1.4, 3.1] 1153 2.0 [1.0, 4.1] 629 1.9 [1.0, 4.1] 524 2.1 [1.0, 4.1]
24–27 1245 2.3 [1.5, 3.7] 637 2.2 [1.4, 3.6] 608 2.4 [1.6, 4.0] 1302 2.3 [1.1, 4.6] 668 2.3 [1.1, 4.4] 634 2.5 [1.1, 5.1]
20–23 593 2.6 [1.7, 4.3] na na 593 2.6 [1.7, 4.3] 617 2.4 [1.2, 5.2] na na 617 2.4 [1.2, 5.2]
10–19 324 3.0 [2.0, 5.5] na na 324 3.0 [2.0, 5.5] 348 2.5 [1.0, 5.4] na na 348 2.5 [1.0, 5.4]
<10 111 3.3 [2.1, 6.0] na na 111 3.3 [2.1, 6.0] 114 3.7 [1.5, 8.3] na na 114 3.7 [1.5, 8.3]
ADL [points] 5–6 3112 2.2 [1.5, 3.6] 1258 2.0 [1.3, 3.3] 1854 2.3 [1.6, 3.7] 3220 2.2 [1.0, 4.4] 1312 2.1 [1.0, 4.3] 1908 2.2 [1.0, 4.5]
3–4 205 3.2 [2.2, 6.2] na na 205 3.2 [2.2, 6.2] 220 3.4 [1.7, 9.3] na na 220 3.4 [1.7, 9.3]
0–2 165 4.2 [2.6, 7.4] na na 165 4.2 [2.6, 7.4] 178 3.9 [1.9, 9.4] na na 178 3.9 [1.9, 9.4]
a: Excluded are individuals with leukocytosis exceeding 10,000/mm3 or treated with glucocorticoids
b: Only individuals without past or current cancer, type 2 diabetes, cardiovascular disease/myocardial infarction/stroke, and with the MMSE score ≥24 and the ADL score 5–6
c: Individuals who did not meet the definition of successful aging
d: Concentrations of IL–6 and CRP are shown as median [1st quartile, 3rd quartile]
n Number of individuals
na Not applicable
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reflecting good physical and cognitive performance, were
included in this subgroup.
The CRP concentration was significantly associated
with BMI (p < 0.001 for the entire study group, p < 0.001
for the successfully aging subgroup, and p < 0.001 for
study participants with aging-related diseases/disability).
The CRP concentration was the lowest in the group of
normal-weight individuals and then systematically in-
creased as BMI increased. Notably, it was also higher
in individuals with a BMI <18.5 kg/m2 compared with
normal-weight study subjects. Additionally, the CRP
concentration was associated with fasting glucose in
the entire study group (p = 0.003) and individuals with
aging-related diseases/disability (p = 0.006) and was the
highest in individuals with a glucose level ≥140 mg/dL.
Notably, in the successfully aging subgroup no association
was found. The CRP concentration was also associated
with eGFR (p < 0.001 for the entire study group, p < 0.001
for the successfully aging subgroup, and p < 0.001 for par-
ticipants with aging-related diseases/disability) and was
the highest in individuals with the lowest eGFR, as well as
with heart rate (p < 0.001, p < 0.001 and p < 0.001) where it
was the highest in individuals with a heart rate >80/min.
Furthermore, the CRP concentration was also associated
with smoking status in the entire study group (p = 0.005)
and in individuals with aging-related diseases/disability
(p = 0.002) where it was the highest in current smokers;
however, no association with smoking status was found
in the successfully aging subgroup. Finally, The CRP
concentration was negatively associated with the level
of HDL cholesterol (p < 0.001, p < 0.001 and p < 0.001)
(Table 2). The multifactorial analysis including age, gen-
der, BMI, HDL, eGFR and smoking status revealed that all
of the factors remained significantly associated with CRP
in the entire study group and successfully aging subgroup,
whereas age lost its significant association in the subgroup
of participants with aging-related diseases/disability.
We also found that higher CRP levels were associated
with poorer physical performance (lower ADL score)
and poorer cognitive performance (lower MMSE score)
(all p < 0.001 for the entire study group as well as for
both subgroups, Table 2). The multifactorial analyses
that were adjusted for age, gender, BMI, HDL, eGFR and
smoking status revealed that in the entire studied group
the ADL and MMSE scores remained related to CRP at
statistically significant level (p = 0.019 and p < 0.001 re-
spectively). We did not perform such an analysis in the
successfully aging subgroup because only individuals
with the highest ADL and MMSE scores were included
in this subgroup.
Association between IL-6 and CRP levels and survival
The 1-year mortality rate was 6.6 %, 2.6 %, and 8.8 % for
the entire study group, the successfully aging subgroup,
and study participants with aging-related diseases/disabil-
ity, respectively. In the univariate analysis, longer survival
was associated with a lower IL-6 concentration: HR =
1.077 per each pg/mL (95 % CI: 1.068–1.086, p < 0.001) in
the entire study group, HR = 1.163 per each pg/mL (95 %
CI: 1.128–1.199, p < 0.001) in the successfully aging sub-
group, and HR = 1.063 per each pg/mL (95 % CI: 1.052–
1.074, p < 0.001) in individuals with aging-related diseases/
disability. Longer survival was also associated with a lower
CRP concentration: HR = 1.025 per each mg/L (95 % CI:
1.020–1.029, p < 0.001) in the entire study group, HR =
1.074 per each mg/L (95 % CI: 1.047–1.100, p < 0.001)
in successfully aging study participants, and HR = 1.020
per each pg/mL (95 % CI: 1.015–1.025, p < 0.001) in the
remaining participants.
The results of the univariate analysis were consistent
with the Kaplan-Meier survival curves, in which higher
concentrations of IL-6 and CRP were associated with a
lower probability of survival in the entire group of seniors,
in successfully aging ones, as well as in individuals with
aging-related diseases/disability (all p < 0.001) (Figs. 1, 2).
A statistical model was applied that included IL-6
value, gender, age, BMI, HDL, LDL, eGFR and smoking
status. We found that longer survival was associated
with a lower IL-6 concentration, even after adjusting for
these covariates, in the entire study group: HR = 1.042
per each pg/mL (95 % CI: 1.029–1.055, p < 0.001), the
successfully aging subgroup: HR = 1.112 per each pg/mL
(95 % CI: 1.069–1.155, p < 0.001), as well as in study par-
ticipants with aging-related diseases/disability: HR =
1.031 per each pg/mL (95 % CI: 1.018–1.045, p < 0.001).
We also tested a model that included CRP value, gender,
age, BMI, HDL, eGFR and smoking status, and found that
longer survival was associated with a lower CRP concentra-
tion after adjusting for these factors in the entire group of
seniors: HR = 1.017 per each mg/L (95 % CI: 1.012–1.023,
p < 0.001), in the successfully aging subgroup: HR = 1.035
per each mg/L (95 % CI: 1.021–1.050, p < 0.001), and in
the remaining study participants with aging-related di-
seases/disability: HR = 1.013 per each pg/mL (95 % CI:
1.007–1.019, p < 0.001).
Discussion
It is well documented that chronic inflammation is asso-
ciated with aging-related morbidity [13–22], and with
mortality in affected individuals [15, 17, 23–25]. Therefore,
the present study evaluated a large group of Eastern Euro-
pean Caucasian seniors to determine whether results of a
single measurement of the levels of two proinflammatory
factors, IL-6 and CRP, were associated with biochemical
and functional parameters and whether they were predic-
tors of mortality. We performed this analysis for the entire
study group of ≥65 year-old seniors who were not prese-
lected on the basis of their health and functional status, as
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well as for subgroups of successfully aging individuals and
individuals with aging-related chronic diseases/disability.
There is no single generally agreed upon definition of
successful aging. It is usually defined as survival to an
older age while being free of aging-associated diseases,
such as cardiovascular disease, cancer, neurodegeneration,
and type 2 diabetes, with good physical and cognitive
functioning [35]. This “biological” definition is sometimes
augmented by a requirement to have good social function-
ing and high life satisfaction [35]. However, for the pur-
pose of this study, in which we analyzed biological factors
associated with aging, we used the most common defin-
ition that is limited to the biology of aging. An additional
reason for such limitation was that social functioning and
life satisfaction might be significantly influenced by non-
biological factors such as income, family situation, or place
of residence. We found that IL-6 and CRP levels were
good predictors of physical and cognitive performance
and mortality not only in the entire aging study group and
in individuals with aging-related diseases/disability, but
also in individuals who were aging successfully.
IL-6 is known to induce the production of CRP in the
liver [36]. Therefore, as expected, the levels of IL-6 and
CRP were correlated in the elderly subjects in this study.
However, aging-related changes in CRP did not accurately
reflect changes in IL-6. Impaired liver function, which
Fig. 2 Kaplan-Meier survival curves for the elderly population that was classified according to CRP concentrations. a. In the successfully aging
subgroup, the 1-year mortality rates were 1.6 % for ≤3 mg/L, 2.8 % for 3.1–10 mg/L, and 8.8 % for >10 mg/L. The differences between ≤3 mg/L
and the other concentration ranges were significant (all p < 0.001). b. In the subgroup of individuals who suffered from aging-related diseases/
disability, the 1-year mortality rates were 6.3 % for ≤3 mg/L, 10.3 % for 3.1–10 mg/L, and 19.2 % for >10 mg/L. The differences between ≤3 mg/L and
other concentration ranges were significant (all p < 0.001)
Fig. 1 Kaplan-Meier survival curves for the elderly population that was classified according to quartiles of IL-6 concentrations. a. In the successfully
aging subgroup, the 1-year mortality rates were 1.0 % for the <1st quartile, 0.6 % for the 1st-2nd quartile, 4.1 % for the 2nd-3rd quartile, and 6.8 %
for the >3rd quartile. The differences between the <1st quartile and all of the other quartiles were significant (all p < 0.001). b. In the subgroup of
individuals who suffered from aging-related diseases/disability, the 1-year mortality rates were 2.9 % for the <1st quartile, 5.7 % for the 1st-2nd quartile,
10.0 % for the 2nd-3rd quartile, and 15.8 % for the >3rd quartile. The differences between the <1st quartile and all of the other quartiles were significant
(all p < 0.001)
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could be expected mainly in the subgroup of individuals
who did not age successfully, might affect CRP production.
We tested this hypothesis by correlating aspartate trans-
aminase (AST) and alanine transaminase (ALT) levels with
the CRP level and found that some negative correlations
were significant, but all of the correlation coefficients were
extremely low (data not shown). Therefore, we conclude
that liver function had no significant influence on CRP
production in our study group. Another plausible explan-
ation for the lack of complete correspondence between IL-
6 and CRP concentrations is that CRP production is
affected by other cytokines, such as IL-1 and IL-17 [36],
which were not measured in the present study.
Notably, although statistically significant, the differences
between mean IL-6 and CRP concentrations in the success-
fully aging participants and remaining study participants
who suffered form from aging-related diseases/disability
were only approximately 20 % (2 pg/mL vs. 2.5 pg/mL and
2.1 mg/L vs. 2.5 mg/L, respectively). Therefore, the question
arises as to the reason why, despite such a small differences,
some individuals experienced healthy aging, while others
suffered from aging-related diseases. The most likely ex-
planation for this phenomenon is that the phenotype of
aging results not only from the amount of the examined
proinflammatory factors, but also from a balance between
numerous proinflammatory and antiinflammatory agents
(inflammaging vs. anti-inflammaging) [37, 38]. Moreover,
the effect of such a balance might be modified by other
conditions, such as diet, body fat content, level of physical
activity, smoking, and other disease risk factors, including
genetic background [39–42].
Another important finding of this study was that the
lowest IL-6 levels were found in normal-weight and over-
weight individuals, and the lowest CRP levels were found
in normal-weight individuals. Such a U-shaped relationship
between BMI and proinflammatory factors supports the
theory of the “obesity paradox” stating that in the elderly,
lower morbidity and mortality are associated with a normal
body weight or being overweight [43–46], whereas being
underweight or obese (especially morbidly obese) poses a
high risk of mortality. Based on the present results, we
speculate that this phenomenon might be, at least partially,
attributable to an increase in systemic inflammation in ex-
treme weight groups. Notably, in our study participants, a
BMI <18.5 kg/m2 was associated with the highest IL-6 level
and, to a lesser extent, an increase in CRP level. Data that
were obtained from the revised Mini Nutritional Assess-
ment Short Form and serum biochemical parameters indi-
cated that these individuals were undernourished and
vitamin D-deficient (even though, some of them were still
able to meet our phenotypic criteria for successful aging).
The available data suggest that poor nutritional status and
vitamin D deficiency might be associated with increased
levels of proinflammatory factors, such as TNF-α, IL-6,
and CRP [47–49]. Therefore, in our underweight elderly
patients, high levels of IL-6 and CRP might result from a
cumulative action of immunoaging and undernutrition/
malnutrition.
We also found that the IL-6 concentration was nega-
tively associated with concentrations of total cholesterol
and its high- and low-density fractions in the entire
studied population and in its subgroups, while CRP was
negatively associated only with HDL. Such findings indi-
cate that low cholesterol levels in the elderly might have
adverse effects, such as the increased level of IL-6 that we
detected in the present study. Our results are partially con-
sistent with previous studies that reported the existence of
similar correlations in oldest-old group of ≥85 year-old in-
dividuals [50, 51]. However, we found that such relation-
ships were also true for seniors who were ≥65 years old.
Longitudinal studies indicate that aging might be associ-
ated with a decrease in total cholesterol and LDL levels
and an increase in HDL levels, which is mostly a result of
decreasing weight [52]. On the other hand, increased levels
of proinflammatory factors are attributable to a higher
body weight [53, 54]. Therefore, an inverse relationship be-
tween lipids and proinflammatory factors in seniors might
be unrelated to total adipose tissue content but may be
related to the abdominal localization of adipose tissue
[55, 56]. Alternatively, adipose tissue might not be a
key factor in the interplay between lipids and inflamma-
tion in older age groups.
Consistent with previous findings [23, 57], we found
that higher IL-6 and CRP levels were associated with
poorer cognitive and/or functional performance, as well
as with a higher risk of mortality. This could be explained
by the fact that aging-associated chronic inflammation is
one of the major causes of aging-related diseases, that
might negatively affect the aging phenotype and shorten
one’s lifespan [13–22]. However, we found that higher
levels of IL-6 and CRP posed an even higher risk of all-
cause mortality in physically and cognitively healthy, suc-
cessfully aging individuals who did not suffer from major
aging-related diseases, reflected by 1-year mortality rates
(see Figs. 1 and 2 legends), and confirmed by 3-year mor-
tality rates (IL-6: 2.9 % for <1st quartile, 6.9 % for 1st-2nd
quartile, 14.0 % for 2nd-3rd quartile and 25.3 % for >3rd
quartile of IL-6 concentration; because there is no estab-
lished “normal” IL-6 concentration range, we divided the
study subjects into IL-6 concentration quartiles; CRP:
7.3 % for ≤3 mg/L, 13.2 % for 3.1-10 mg/L, and 27.2 %
for >10 mg/L). Although these deaths could be partially
attributed to newly diagnosed aging-associated diseases
[21], we speculate that in the individuals who met our
criteria of successful aging, elevated levels of proinflam-
matory factors may serve as an indicator of the in-
creased risk of death or may actually be associated with
such risk through the activation of as-yet unidentified
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pathological mechanisms other than those that lead to car-
diovascular disease, diabetes, cancer, or neurodegeneration.
Finally, we found that low-dose acetylsalicylic acid, which
is very commonly administered in the elderly population
for prevention of cardiovascular events, did not affect IL-6
or CRP levels, which was consistent with recently pub-
lished results regarding 35 to 75-year-old participants of
the Swiss CoLaus Study [58]. This previous study and our
present results suggest that the well-studied cardioprotec-
tive action of low-dose acetylsalicylic acid may not be at-
tributable to the lowering of IL-6 or CRP levels but rather
other mechanisms, such as the modification of other cyto-
kine concentrations.
The strengths of this study reside in the large size of
the study group, the mode of recruitment (from urban
and rural municipalities), the equally-sized 5-year age
cohorts, the equal representation of both sexes, and de-
tailed baseline clinical and biochemical data that allowed
us to identify the group of successfully aging individuals
based on various parameters [30]. On the other hand,
one limitation of the present study was that not all of
the study participants had their blood drawn. However,
those who did not provide blood were not preselected on
the basis of any condition, and we believe that the chance
of bias for this reason is relatively low. Another limitation
is that the lack of data regarding morbidity after the base-
line interview prevented us from determining whether or
not and to what extent new cases of aging-related diseases
might explain associations between IL-6 and CRP levels
and mortality in successfully aging individuals.
Conclusions
In the present study, IL-6 and CRP levels in the elderly
systematically increased in an age-dependent manner
in the entire study group, the successfully aging sub-
group, and in individuals who suffered from aging-related
diseases/disability. Higher IL-6 and CRP levels were asso-
ciated with poorer cognitive and/or functional perform-
ance, and a higher risk of mortality also in successfully
aging individuals. Our data support the notion that a
single measurement of IL-6 and/or CRP concentrations in
elderly individuals is a good predictor of physical and cog-
nitive performance and mortality in the entire elderly
population, including successfully aging individuals.
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